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Abstract Classic infantile Pompe disease is an inherited
generalized glycogen storage disorder caused by deficiency
of lysosomal acid α-glucosidase. If left untreated, patients
die before one year of age. Although enzyme-replacement
therapy (ERT) has significantly prolonged lifespan, it has
also revealed new aspects of the disease. For up to 11 years,
we investigated the frequency and consequences of facial-
muscle weakness, speech disorders and dysphagia in long-
term survivors. Sequential photographs were used to
determine the timing and severity of facial-muscle weak-
ness. Using standardized articulation tests and fibreoptic
endoscopic evaluation of swallowing, we investigated
speech and swallowing function in a subset of patients.
This study included 11 patients with classic infantile Pompe
disease. Median age at the start of ERT was 2.4 months
(range 0.1-8.3 months), and median age at the end of the
study was 4.3 years (range 7.7 months −12.2 years). All
patients developed facial-muscle weakness before the age
of 15 months. Speech was studied in four patients.
Articulation was disordered, with hypernasal resonance
and reduced speech intelligibility in all four. Swallowing
function was studied in six patients, the most important
findings being ineffective swallowing with residues of food
(5/6), penetration or aspiration (3/6), and reduced pharyn-
geal and/or laryngeal sensibility (2/6). We conclude that
facial-muscle weakness, speech disorders and dysphagia are
common in long-term survivors receiving ERT for classic
infantile Pompe disease. To improve speech and reduce the
risk for aspiration, early treatment by a speech therapist and
regular swallowing assessments are recommended.
Introduction
Pompe disease (glycogen storage disease type II, acid
maltase deficiency, OMIM # 232300) is a rare autosomal
recessive lysosomal storage disorder caused by mutations in
the gene-encoding acid α-glucosidase (EC 3.2.1.20) (Van
der Ploeg and Reuser 2008; Hirschhorn and Reuser 2001).
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resulting in the classic infantile form of Pompe disease,
which was first described by Pompe in 1932 (Pompe 1932).
Symptoms are caused by glycogen accumulation, mainly in
skeletal, cardiac and smooth muscle, but also in other
tissues, including the central and peripheral nervous system.
In the first months of life, patients present with progressive
muscle weakness, hypertrophic cardiomyopathy, respiratory
problems and feeding difficulties. If untreated, this leads to
death before the age of one year (Van den Hout et al. 2003;
Kishnani et al. 2006a).
Although the lifespan of classic infantile Pompe patients
has been significantly prolonged, and although motor
functioning is improved by enzyme-replacement therapy
(ERT), various extents of muscle weakness remain (Van
den Hout et al. 2000, 2004; Kishnani et al. 2009; Nicolino
et al. 2009; Muller et al. 2009; Kishnani et al. 2007;
Kishnani et al. 2006b; Klinge et al. 2005a, b; Amalfitano et
al. 2001; Chakrapani et al. 2010). This study focuses on
weakness of the facial and bulbar muscles.
We simultaneously examined the prevalence and con-
sequences of facial-muscle weakness, speech disorders and
dysphagia in a cohort of patients with classic infantile
Pompe disease who had been treated with ERT over a long
period, in some cases up to 11 years.
Patients and methods
Patients
The study comprised 11 patients with classic infantile
Pompe disease treated with ERT between 1999 and 2010 at
Erasmus MC University Medical Center, Rotterdam, the
Netherlands. Classic infantile Pompe disease was defined
as 1.) symptoms of muscle weakness within six months of
birth, 2.) hypertrophic cardiomyopathy, and 3.) severe GAA
(the gene-encoding acid α-glucosidase) mutations on both
alleles. The diagnosis was confirmed by an enzyme-activity
assay in leukocytes or fibroblasts. Patients were enrolled in
clinical trials that investigated the safety and efficacy of
ERT with recombinant human α-glucosidase (20 mg/kg/
two weeks to 40 mg/kg/week). The Institutional Review
Board approved the studies, and written informed consent
was obtained from all parents.
Facial-muscle weakness
To examine the onset offacial-muscle weakness, we collected
photographsofthefacetakenoveraperiodof24monthsfrom
the start of ERT. For this we used standardized photographs
and videos taken every three months. The photographs were
ordered arbitrarily and evaluated independently by three
neurologists. The evaluators stated whether facial-muscle
weakness was present, and, whether it was mild or severe.
Facial-muscleweaknesswasdefinedasanexpressionlessface
with an open drooping or tent-shaped mouth (Dubowitz
1978). To accept any judgement, the agreement of at least
two evaluators was needed. If this was impossible, the
evaluation was considered not to be applicable.
To further characterize facial-muscle weakness, the eval-
uators scored whether the following clinical features were
present, absent or impossible to judge: ptosis, sunken cheeks,
drooping of the lower lip, absence of the nasolabial folds, and
absence of horizontal forehead lines. Ptosis was considered to
be present when the upper eyelid was less than 2 mm from
midpupil,orwhenasymmetrybetweentheleftandrightupper
eyelid was greater than 2 mm. A recent photograph of each
patient was collected to analyse progression over time.
Speech and swallowing function
Between 2008 and 2010, speech was assessed in patients
older than 24 months or in those who spoke more than ten
words (n=4). Swallowing function was assessed in patients
who were not fed by percutaneous endoscopic gastrostomy
(n=6). Assessments were repeated after at least one year.
Speech
First, a speech therapist conducted a thorough orofacial
observation to detect whether speech was impaired by
weakness or reduced movements of the lip and tongue. To
evaluate speech, a modified form of the Dutch Schisis
Articulation Examination was used, which examines spon-
taneous language, and the repetition of phonemes and
words. The following items were examined: 1.) articulatory
disorders (i.e. mispronunciation of speech sounds), 2.)
hypernasal resonance (i.e. increased resonance by the nasal
cavity), and 3.) speech intelligibility.
Additionally, a neuropsychologist tested for dysarthria
using the Mayo Clinic Lists (Darley et al. 1969b), which also
investigates respiration, phonation (i.e. the characteristics of
voice production by the larynx), and prosody (i.e. speed and
rhythm of speech).
Swallowing function
The speech therapist obtained a feeding history
from all parents.
Pharyngeal swallowing function was assessed by an
experienced otolaryngologist using fibreoptic endoscopic
evaluation of swallowing (FEES) (Langmore et al. 1988).
First, the masticatory pattern was investigated. Then, after the
fibrescope had been introduced, the anatomy and function of
the swallowing apparatus were examined: Velopharyngeal
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examined during speech, and the pharynx and larynx were
screened for deviant anatomy, reduced pharyngeal squeeze,
and impaired laryngeal function.
Next, pharyngeal swallowing function was examined
while patients ingested food in a sitting position. Observa-
tion of swallowing function included premature spillage of
food, delayed swallowing, nasal regurgitation, pharyngeal
food residue, and penetration and aspiration of the food or
pooling secretions. Penetration was defined as leakage of
food into the laryngeal vestibule up to the level of the true
vocal cords; aspiration was defined as leakage into the
laryngeal vestibule below this level (Langmore 2001).
Finally, we observed the sensory reaction of the pharynx
and larynx.
Associated clinical outcome measures
At the time of speech and swallowing assessments, relevant
clinical data on feeding (orally or tube feeding), airway
infections, motor development, and hearing loss (Van
Capelle et al. 2010) were collected.
Results
Patients
Eleven patients participated in this study. Table 1 summa-
rizes each patient’s clinical features. At the start of ERT all
patients had symptoms of Pompe disease. All were
hypotonic, and eight were fed by nasogastric tube.
Facial muscle weakness
In total, 96 photographs were collected of 11 patients. The
median age at the first photo was 2.3 months (age range
0.1-8.8 months); the median age at the last was 49.2 months
(age range 6.9 months-11.6 years).
Between the ages of 1.0 and 15.0 months (Table 1,m e d i a n
6.6 months), all patients developed evident signs of facial-
muscle weakness, even when ERT was started very early.
When such weakness was first observed, its severity in most
patients (9/11) was considered to be mild. The main
characteristics were sunken cheeks (8/11) and a drooping
lower lip (9/11). While the absence of the nasolabial fold and
forehead lines were difficult to judge, four patients clearly
had diminished nasolabial folds. Only one patient had ptosis.
The final photographs show that, despite ERT, facial-
muscle weakness became severe in 7/11 patients (Fig. 1).
While the main features were still sunken cheeks (10/11)
and drooping of the lower lip (9/11), facial expression was
clearly reduced by diminished nasolabial folds (7/11) and
forehead lines (5/11). The number of patients with ptosis
rose to four.
Speech and swallowing function
Speech
Speech was assessed in four patients at a median age of
4.1 years (age range 2.0-9.9 years, supplementary Table 2).
Orofacial observation showed that the speech of all four
was impaired by reduced movement and/or weakness of the
lip and/or tongue. Their articulation was disordered,
Table 1 Patient characteristics and development of facial muscle weakness in 11 patients with classic infantile Pompe disease treated with ERT
Patient Gender Age at
diagnosis
(months)
Age at the
start of ERT
(months)
NGT at the
start of
ERT
Age at
study end
(years)
Invasive
ventilation**
(months)
Maximal
motor
milestone
Severity of first
observed FMW**
(months)
Severity of FMW
on most recent
photo** (years)
1 M 0.7 3.8 N 11 No Walking Mild (6.6) Mild (11.6)
2 F 3.6 7.2 Y 12 7† Tetraplegic Severe (1.0‡) Severe (11.4)
3 F 0.6 3.0 Y 4* 26 Sitting Mild (5.5) Severe (3.4)
4 F 6.2 8.3 Y 12 11 Tetraplegic Mild (9.0) Severe (6.2§)
5 M 0.2 1.9 Y 4* 24 Walking Mild (13.8) Severe (4.1)
6 M 0.7 1.2 Y 6 No Walking Mild (3.4) Severe (6.0)
7 F 0.2 0.5 Y 5 No Walking Mild (12.4) Mild (5.5)
8 F 3.2 3.6 Y 0.8* No Minimal movements Mild (6.9§) Mild (0.6§)
9 M 0.1 0.1 Y 3 33 Walking Mild (15.0) Severe (3.0)
10 M 2.0 2.2 N 3 No Sitting Severe (2.0) Severe (2.7)
11 F 2.3 2.4 N 2 No Walking Mild (2.3) Mild (1.7§)
F=Female, M=Male, NGT=Nasogastric tube feeding, Y=Yes, N=No, *=Died, **=Age in months or years, †=Invasive ventilation before start
of ERT, FMW=Facial muscle weakness, ‡=Photographs were available before start of ERT, §=last available picture due to referral to treatment
abroad (4), early death (8), and short treatment duration at the end of this study (11)
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cluster reductions, mild to moderate hypernasal resonance,
and significantly impaired speech intelligibility. Together,
this suggested velopharyngeal incompetence.
Three patients were reassessed at a median age of 5.5 years
(age range 5.1-11.1 years). In the period between the first and
secondassessment,nomajorchangesinorofacialhypotoniaor
speech were observed, although speech therapy had improved
the active articulatory compensation. Additional investigation
of dysarthria in these three patients showed disorders in
respiration, phonation and prosody. They spoke in short
sentences in a monotone, hoarse wet voice with monoloud-
ness. These features are specific for flaccid dysarthria.
Swallowing function
Swallowing function was assessed in six patients at a median
age of 3.0 years (age range 8.0 months to 9.9 years). Feeding
difficulties were reported (5/6), and comprised all parameters
(seesupplementary Table2). Patient 9 was fed completely by
nasogastric tube, and ingested only water orally. Observation
of mastication revealed impaired mastication in two patients.
Fibreoptic endoscopic examinations of swallowing
showed that five of the six patients had varying extents of
dysphagia; only the youngest had no swallowing abnor-
malities. Reduced velopharyngeal closure was found in four
patients, and caused nasal regurgitation in two. Although
the anatomy of the swallowing apparatus and function of
the larynx were normal, pharyngeal muscle contraction was
reduced (5/6). This resulted in pooling secretions in the
pharynx (4/6), which, in two patients, contained remnants
of a previous meal (Fig. 2a).
Swallowing of various textures of food could be
examined in four patients, whereas swallowing function of
two patients who refused to eat during the examination (9
and 10) was evaluated on the basis of dry swallows. In all
patients with insufficient muscle contraction of the pharynx
(5/6), residues of food or saliva remained present at the
valleculae, pharyngeal wall, pyriform sinuses and postcri-
coid. Because patients used no protective reflexes such as
coughing or swallowing to try to clear the food, it was clear
that the sensory reaction of the pharynx was impaired (2/6).
In three patients, pharyngeal residues resulted in penetration
of food or saliva (Fig. 2b). In two of the six patients, the
sensory reaction of the larynx was impaired.
Swallowing function was reassessed in four patients, at a
median age of 5.3 years (age range 2.0-11.1 years). In three
patients it remained stable; in the other (Patient 7), it
deteriorated, leading to aspiration, premature spillage of
food, and delayed onset of swallowing.
Fig. 1 Developmentoffacialmuscleweaknessovertimeinfourpatients
with classic infantile Pompe disease treated with ERT. Per patient,
comparison of the first photograph which showed the first signs offacial-
muscle weakness (a-d) with the most recent photograph (e-h)s h o w e d
that facial muscle weakness remained mild in two patients (a and b
compared to e and f), but became severe in one patient (c compared to
g). One patient presented with severe facial muscle weakness at the age
of 1 month; this persisted over time (d compared to h)
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At the start of ERT, feeding through a nasogastric tube
(NGT) was required by eight of the 11 patients. By the end
of the study, five patients were completely orally fed. Their
ages were 2, 3, 6, 6, and 11 years. Two patients have never
required NGT feeding since ERT began.
Hearing was impaired in all patients except Patient 9,
their hearing deficits ranging from 30–90 dB (Van Capelle
et al. 2010). Three of the four patients whose speech was
evaluated already had hearing aids at first evaluation. The
other patient (7) needed hearing aids later; he had a mild
hearing loss of 30–40 dB.
Five of the six patients whose swallowing function was
assessed, learned to walk (see Table 1 and supplementary
Table 2 for motor outcome), and three of the same six
patients had recurrent respiratory infections.
Discussion
The longest survivors receiving enzyme-replacement ther-
apy for infantile Pompe disease are currently 12 years old.
It is evident not only that ERT has significantly increased
survival, but also that it greatly affects these children’s
motor performance. However, this longer survival has also
highlighted previously unrecognized aspects of the disease.
Noting that many children had developed facial-muscle
weakness over time, we investigated the frequency and
consequences of facial-muscle weakness, speech disorders
and dysphagia in long-term survivors.
In all 11 patients, facial-muscle weakness had developed
before the age of 15 months. When first observed, its main
features were poor facial expression, sunken cheeks and
drooping of the lip. Over the years, all facial muscles
seemed to become affected. FEES examinations showed
weakness of the bulbar muscles, with velopharyngeal
incompetence and reduced muscular contraction of the
pharynx.
This muscle weakness affected daily functioning in four
main ways. 1.) All patients had poor facial expression. 2.)
Four children developed a bilateral ptosis over time, which
was so severe in one child that surgical correction was
required (Slingerland et al. 2011). 3.) Speech was abnormal,
characterized by disordered articulation, hypernasality, and
lower intelligibility – all typical of velopharyngeal incompe-
tence (Darley et al. 1969a), as suggested earlier by Muller et
al. (Muller et al. 2009). 4.) Swallowing was generally weak
andineffective,leavingresiduesoffoodaroundthelarynx,with
penetration in three out of six patients. As some patients lack
protective sensory reactions of the pharynx and larynx,
aspirations and micro-aspirations may easily occur and go
unnoticed. In retrospect, we suspect that this phenomenon
explains the recurrent airway infections in three patients in our
study. As respiratory muscle weakness can easily lead to
respiratory insufficiency, such aspirations and aspiration
pneumonias may be life threatening. As it has proved difficult
to wean patients with classic infantile Pompe off the ventilator,
this is particularly important. Earlier studies have shown that,
despite treatment with ERT, 50% of classic infantile patients
eventually become ventilator dependent, and that respiratory
insufficiency is the main cause of death (Kishnani et al. 2009).
We found no clear relationship between the age at start
of ERT and the point at which facial-muscle weakness
developed, although the severest facial muscle weakness
was found in patients who started ERT late – at 7 and
8 months of age. ERT seemed to reduce feeding difficulties
in some patients. During enzyme therapy, nasogastric tube
feeding could be discontinued in three of eight patients who
needed NGTat start. At the end of the study, five patients in
age ranges from 2–12 years were completely orally fed.
Still, four of these patients showed some signs of
dysphagia. It is noteworthy that the patients who were fed
orally were the best performers. Four of these five patients
Fig. 2 FEES examination in a
6-year old boy with classic
infantile Pompe disease treated
with ERT. Pooled secretions in
the pharynx containing saliva
and remnants of previously eat-
en food at FEES examination
(a), and pharyngeal food residue
with penetration and aspiration
directly after food intake (b)
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study. ERT could not prevent disordered speech, although
the severest speech problems were observed in those with
the poorest motor outcome.
Our study indicated that parents often underreport signs
of choking and swallowing difficulties. Given the findings
of our study, we attach paramount importance to assess-
ments of swallowing function especially in young patients.
To prevent aspiration and pneumonia, it may be advisable
to modify dietary texture, or even to discontinue oral
feeding in high-risk patients. A low maintenance dose of
antibiotics may also be helpful. To improve speech, feeding
and swallowing difficulties as much as possible, we
recommend early examination and treatment by a speech
therapist. In patients with severe hypernasal resonance,
however, only slight gains on speech can be achieved by
behavioural exercises. Other options to improve speech
include a palatal lift prothesis, or surgical interventions
such as pharyngoplasty or a pharyngeal flap (Rudnick and
Sie 2008). But as these may also increase swallowing
difficulties or cause obstructive sleep apnoea, they should
be used with caution. Their overall effect may also be
limited by the residual pharyngeal muscle weakness that
remains in patients with classic infantile Pompe disease.
Hearing loss is common in classic infantile Pompe
patients, and may also impact speech development. We
earlier recommended regular auditory tests, and early
implementation of hearing aids (Van Capelle et al. 2010).
The exact cause of bulbar muscle weakness is unknown.
In infants with Pompe disease, it has been shown that
glycogen accumulates in the tongue of an untreated infant
(Sakurai et al. 1974), but the effect of ERT on bulbar
muscle pathology in these infants has not been studied.
Only one case report addresses the effect of ERT on bulbar
muscle pathology in an adult patient with Pompe disease
and showed that, 21 months after treatment with ERT,
residual storage of glycogen remained in the oesophagus
(Kobayashi et al. 2010). This is in line with results obtained
in Pompe knock-out mice, which showed that extensive
glycogen storage present in bulbar muscles was not
completely cleared by ERT (Bijvoet et al. 1999).
Together, these findings suggest that residual muscle
pathology of the bulbar muscles almost certainly plays a
major role in the speech and swallowing problems
described in this study. It cannot be excluded that a role is
also played by glycogen storage in the nervous system.
Autopsies of untreated patients with classic infantile Pompe
disease have shown glycogen accumulation in the glial cells
of the cortex, thalamus, brainstem, and spinal anterior
motor horns (Gambetti et al. 1971; Mancall et al. 1965;
Martin et al. 1973). Since ERT cannot cross the blood-brain
barrier, ERT is unlikely to affect the glycogen storage in the
central nervous system (Begley et al. 2008).
Certain features of the speech of the children in our
study may reflect flaccid dysarthria (Darley et al. 1969b, a),
a condition caused by damage to the lower motor neurons
emerging from the brainstem. The lower sensibility of the
larynx and pharynx and the delayed swallowing seen in
some patients might also indicate involvement of the
nervous system. Further research is required.
All in all, we could not fully explain why obvious bulbar
muscle weakness developed even in good responders to
ERT with a good motor outcome. If muscle pathology
indeed underlies the clinical problems, this may imply that
bulbar muscles respond less to ERT than the muscles of the
limbs and trunk.
Several studies have sought to explain the differential
response of muscles to ERT. One potential explanation
involved variation in response by different muscle-fibre
types. It was shown in mice with Pompe disease that type 2
muscle fibres were largely resistant to ERT (Raben et al.
2005). In humans, type 1 and type 2a muscle fibres both
responded to enzyme therapy (Drost et al. 2008). Compar-
ison of skeletal muscles from the limb and trunk with
bulbar muscles shows that bulbar muscles have a wider
repertoire of contractile proteins, including developmental
and specialized isoforms of myosin and hybrid fibers that
express two or more isoforms (Hoh 2005; Kent 2004;
Sciote et al. 2003). This might contribute to a lower
response to ERT in these muscles. While the results of our
studies in knock-out mice with Pompe disease have not
confirmed a smaller response of the bulbar muscles, the
situation might be different in humans (Bijvoet et al. 1999).
In conclusion, we have shown that facial-muscle
weakness, speech disorders and dysphagia are prominent
in patients with classic infantile Pompe disease who
survive due to enzyme therapy. Bulbar muscle weakness
caused speech disorders, severely reducing speech
intelligibility, thereby affecting communication and
social interaction. Early treatment by a speech therapist
might help to improve articulation and speech. Similar-
ly, because ineffective swallowing puts patients at risk
for the development of aspiration pneumonias and
respiratory insufficiency, early and regular swallowing
assessments and development of a safe feeding plan are
recommended. Further research is necessary to elucidate
the exact pathophysiology.
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